Literature DB >> 3084250

Purification and reconstitution properties of human placental aromatase. A cytochrome P-450-type monooxygenase.

L Tan, N Muto.   

Abstract

The hemoprotein component of human placental aromatase (estrogen synthetase) has been purified to a high degree of homogeneity by a combination of affinity and adsorption chromatography on aminohexyl-Sepharose, concanavalin-A-Sepharose, and hydroxyapatite. The monomeric form of the enzyme has an Mr of 55000 +/- 1000 as estimated by sodium dodecyl sulfate gel electrophoresis. Its absolute spectrum shows a high-spin Soret band at 394 nm while its reduced, CO-difference spectrum has a maximum at 447 +/- 1 nm. Full reconstitution of aromatase activity was obtained when it was recombined with a homogeneous preparation of the higher-Mr form of either human placental, or bovine hepatic NADPH-cytochrome P-450 reductase. Critical factors for purification of the very unstable, membrane-bound hemoprotein with good retention of activity were, besides the chromatographic sequence, the use of the zwitterionic detergent 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (Chaps) during the solubilization, and the stabilizing effect of the aromatase substrate, 4-androstene-3,17-dione, throughout the procedure. In the presence of NADPH, the reconstituted enzyme system smoothly aromatizes 19-oxoandrostenedione, 19-hydroxyandrostenedione and androstenedione in this order of reactivity. The same reconstituted system also aromatized testosterone, but it was inactive towards 19-norandrostenedione. Known cytochrome P-450 inhibitors decreased its activity. We conclude: (a) the terminal oxidase of human placental aromatase is indeed a cytochrome P-450-type monooxygenase; (b) the multistep aromatization reaction of C19 androstenes is catalyzed by a single enzyme; (c) aromatization of 19-norsteroids reported by other authors must be due to a different aromatase. Experimental data obtained with the reconstituted enzyme are fully compatible with the concept of a reaction mechanism for the aromatization sequence involving an all-trans, antiparallel elimination of the 19-methyl group, the 2 beta proton and the 1 alpha proton, rather than the 1 beta proton, as generally assumed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3084250     DOI: 10.1111/j.1432-1033.1986.tb09574.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  6 in total

Review 1.  Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility.

Authors:  M M de Jong; I M Nolte; G J te Meerman; W T A van der Graaf; J C Oosterwijk; J H Kleibeuker; M Schaapveld; E G E de Vries
Journal:  J Med Genet       Date:  2002-04       Impact factor: 6.318

2.  Kinetic analysis of the three-step steroid aromatase reaction of human cytochrome P450 19A1.

Authors:  Christal D Sohl; F Peter Guengerich
Journal:  J Biol Chem       Date:  2010-04-12       Impact factor: 5.157

3.  Inhibitors of aromatase prevent degradation of the enzyme in cultured human tumour cells.

Authors:  N Harada; O Hatano
Journal:  Br J Cancer       Date:  1998-02       Impact factor: 7.640

4.  Kinetic solvent isotope effect in steady-state turnover by CYP19A1 suggests involvement of Compound 1 for both hydroxylation and aromatization steps.

Authors:  Yogan Khatri; Abhinav Luthra; Ruchia Duggal; Stephen G Sligar
Journal:  FEBS Lett       Date:  2014-07-02       Impact factor: 4.124

5.  Dimethandrolone (7alpha,11beta-dimethyl-19-nortestosterone) and 11beta-methyl-19-nortestosterone are not converted to aromatic A-ring products in the presence of recombinant human aromatase.

Authors:  Barbara J Attardi; Trung C Pham; Lisa C Radler; Janet Burgenson; Sheri A Hild; Jerry R Reel
Journal:  J Steroid Biochem Mol Biol       Date:  2008-06       Impact factor: 4.292

6.  Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk.

Authors:  N Siegelmann-Danieli; K H Buetow
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.